Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Youxi Yu"'
Autor:
Xingtong Wang, Wei Guo, Xiaoju Shi, Yujia Chen, Youxi Yu, Beibei Du, Min Tan, Li Tong, Anna Wang, Xianying Yin, Jing Guo, Robert C. Martin, Ou Bai, Yan Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Highlights • Obesity negatively impacted progression-free survival and overall survival in lymphoma patients while an aggressive tumor growth pattern was found in obesity-lymphoma mice. • S1P-S1PR1/S1PR3-YAP signaling mediated lymphomagenesis con
Externí odkaz:
https://doaj.org/article/bdb3aeff498240b0b2b4c8f510739b12
Publikováno v:
Cell & Bioscience, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract With inconsistent findings, evidence has been obtained in recent years that metabolic disorders are closely associated with the development of lymphomas. Studies and multiple analyses have been published also indicating that some solid tumor
Externí odkaz:
https://doaj.org/article/f7efc26cbee34160b1e64228f8c4e3f1
Autor:
Yan Li, Young K Hong, Xingtong Wang, Harshul Pandit, Qianqian Zheng, Youxi Yu, Xiaoju Shi, Yujia Chen, Min Tan, Zachary Pulliam, Neal Bhutiani, Andrew Lin, Jeremy Badach, Ping Zhang, Robert CG Martin
Publikováno v:
Clinical & Translational Immunology, Vol 11, Iss 12, Pp n/a-n/a (2022)
Abstract Objectives Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a poor prognosis. PDAC has poor response to immunotherapy because of its unique tumour microenvironment (TME). In an attempt to stimulate immunologically silent
Externí odkaz:
https://doaj.org/article/2b4fe68defad4b57a1bec3372df08b6d
Autor:
Robert C.G. Martin, Youxi Yu, Ping Zhang, Guoyue Lv, Xingkai Liu, Xingtong Wang, Xiaoju Shi, Qianqian Zheng, Min Tan, Yan Li
Publikováno v:
International Journal of Biological Sciences
Background: Nonalcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD) and a potential precursor of hepatocellular carcinoma (HCC). In our previous studies, we found that endocrine fibroblast growth facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bf2d2d7a44fb2293282cc05f03d6596
https://doi.org/10.7150/ijbs.58776
https://doi.org/10.7150/ijbs.58776
Publikováno v:
Oncotarget
Purpose: Overexpression of epithelial cell adhesion molecule (EpCAM) correlates with poor prognosis, therapeutic failure and early tumor recurrence in hepatocellular carcinoma (HCC) patients. The tumor microenvironment dictates the fate of tumor-init
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa314da910f46aa4488d9cc4ef4fda5
https://doi.org/10.18632/oncotarget.27454
https://doi.org/10.18632/oncotarget.27454
Publikováno v:
Cellbioscience. 12(1)
With inconsistent findings, evidence has been obtained in recent years that metabolic disorders are closely associated with the development of lymphomas. Studies and multiple analyses have been published also indicating that some solid tumor survivor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb05604cfc42633606f0018ef56d5cc
https://pubmed.ncbi.nlm.nih.gov/35279210
https://pubmed.ncbi.nlm.nih.gov/35279210
Autor:
Qianqian Zheng, Young K. Hong, Yan Li, Robert C.G. Martin, Zachary Pulliam, Youxi Yu, Suping Li, Harshul Pandit
Publikováno v:
Cellular Immunology. 336:66-74
Background Anti-PDL-1 immunotherapy for Hepatocellular Carcinoma (HCC) demonstrated a mixed response. Polycomb Repressor Complex 2(PRC2) contributes to the initiation and progression of HCC by suppressing tumor antigens and inhibiting an immune respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7257eafee1034ba31e7c530ae5abc826
https://doi.org/10.1016/j.cellimm.2018.12.010
https://doi.org/10.1016/j.cellimm.2018.12.010
Publikováno v:
World Journal of Clinical Cases
The most common organ where follicular dendritic cell sarcoma (FDCS) occurs is in cervical lymph nodes, while few cases are found in extranodal organs such as liver, spleen, and soft tissue. This is a case report that FDCS occurs in the hepatogastric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48912809cd670b66924754aa5b97d9c3
http://europepmc.org/articles/PMC6327130
http://europepmc.org/articles/PMC6327130
Autor:
Min Tan, Yan Li, Xingkai Liu, Xingtong Wang, Qianqian Zheng, Ping Zhang, Guoyue Lv, Youxi Yu, Xiaoju Shi, Robert C.G. Martin
BackgroundPharmacological application of the endocrine fibroblast growth factor15/19 (FGF15/19) and FGF21 holds great promise to be effective therapeutic agents for treating nonalcoholic steatohepatitis (NASH), which is the most severe form of non-al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a87ed009b7ff0984e63a666cbcd8a66
https://doi.org/10.21203/rs.3.rs-146881/v1
https://doi.org/10.21203/rs.3.rs-146881/v1
Autor:
Qianqian, Zheng, Robert C, Martin, Xiaoju, Shi, Harshul, Pandit, Youxi, Yu, Xingkai, Liu, Wei, Guo, Min, Tan, Ou, Bai, Xin, Meng, Yan, Li
Publikováno v:
Theranostics
Rationale: Hepatocellular carcinoma (HCC) has been increasingly recognized in nonalcoholic steatohepatitis (NASH) patients. Fibroblast growth factor 21 (FGF21) is reported to prevent NASH and delay HCC development. In this study, the effects of FGF21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::134a1da81399712b8a07bd179fb7d483
https://pubmed.ncbi.nlm.nih.gov/32929325
https://pubmed.ncbi.nlm.nih.gov/32929325